Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

"The urgency to increase awareness about prostate cancer is underscored by our most recent data and analysis," says William L. Dahut, MD.

“Our study reveals potential differences in tolerance and effectiveness of AR inhibitors in practice, which can help clinicians and patients with treatment decisions," says Daniel J. George, MD.